Show simple item record

dc.contributor.authorDu Jardin, Kristian Gaarn
dc.contributor.authorWegener, Gregers
dc.contributor.authorMüller, Heidi Kaastrup
dc.contributor.authorElfving, Betina
dc.contributor.authorDale, Elena
dc.date.accessioned2017-03-29T11:37:34Z
dc.date.available2017-03-29T11:37:34Z
dc.date.issued2016
dc.identifier.citationDu Jardin, K.G. et al. 2016. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: a critical review. Progress in neuro-psychopharmacology & biological psychiatry, 71:27-38. [https://doi.org/10.1016/j.pnpbp.2016.05.007]en_US
dc.identifier.issn0278-5846
dc.identifier.urihttp://hdl.handle.net/10394/20984
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0278584616300793
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2016.05.007
dc.description.abstractA single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist, may alleviate depressive symptoms within hours of administration in treatment resistant depressed patients, and the antidepressant effect may last for several weeks. These unique therapeutic properties have prompted researchers to explore the mechanisms mediating the antidepressant effects of ketamine, but despite many efforts, no consensus on its antidepressant mechanism of action has been reached. Recent preclinical reports have associated the neurotransmitter serotonin (5-hydroxytryptamine; 5-HT) with the antidepressant-like action of ketamine. Here, we review the current evidence for a serotonergic role in ketamine's antidepressant effects. The pharmacological profile of ketamine may include equipotent activity on several non-NMDA targets, and the current hypotheses for the mechanisms responsible for ketamine's antidepressant activity do not appear to preclude the possibility that non-glutamate neurotransmitters are involved in the antidepressant effects. At multiple levels, the serotonergic and glutamatergic systems interact, and such crosstalk could support the notion that changes in serotonergic neurotransmission may impact ketamine's antidepressant potential. In line with these prospects, ketamine may increase 5-HT levels in the prefrontal cortex of rats, plausibly via hippocampal NMDA receptor inhibition and activation of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors. In addition, a number of preclinical studies suggest that the antidepressant-like effects of ketamine may depend on endogenous activation of 5-HT receptors. Recent imaging and behavioral data predominantly support a role for 5-HT1A or 5-HT1B receptors, but the full range of 5-HT receptors has currently not been systematically investigated in this context. Furthermore, the nature of any 5-HT dependent mechanism in ketamine's antidepressant effect is currently not understood, and therefore, more studies are warranted to confirm this hypothesis and explore the specific pathways that might implicate 5-HTen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectKetamineen_US
dc.subjectSerotoninen_US
dc.subjectAntidepressanten_US
dc.subjectGlutamateen_US
dc.titlePotential involvement of serotonergic signaling in ketamine's antidepressant actions: a critical reviewen_US
dc.typeArticleen_US
dc.contributor.researchID22353003 - Wegener, Gregers


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record